Highest-materiality recent filing
IDEX Q1 adj. EPS $2.00 (+14% YoY); raises FY organic growth to 3-4% from 1-2%; record orders $988M
Sales $887M (+9% reported, +5% organic); record orders $988M (+13% reported, +10% organic).
IDEX Q4 record sales $899M (+4%), adjusted EPS $2.10 (+3%); FY 2026 guidance: adj. EPS $8.15-$8.35
Q4 sales $899M, +4% reported (+1% organic); record orders $979M, +20% reported (+16% organic).
IDEX appoints Sean Gillen as CFO, effective Jan 5, 2026; CHRO Melissa Flores departing
Sean Gillen named SVP & CFO, effective Jan 5, 2026; Akhil Mahendra returns to VP Corporate Development.
IDEX Q3 record sales $879M (+10% YoY); adj EPS $2.03 (+7%); narrows FY outlook
Record sales $879M (+10% reported, +5% organic); record orders $880M (+13% reported, +7% organic).
IDEX increases share repurchase authorization to $1B and declares $0.71 quarterly dividend
Board authorized additional $635M share repurchase; total available now ~$1B including $365M remaining.
IDEX Q2 record sales $865M (+7%); cuts FY adjusted EPS guidance to $7.85-$7.95
Q2 reported diluted EPS $1.74 (-6% YoY); adjusted EPS $2.07 (flat YoY), beating expectations.
IDEX Q1 adjusted EPS $1.75, down 7% YoY; record orders $872M
Record orders $872M (+6% reported, +1% organic); sales $814M (+2% reported, -1% organic).
Q4 record sales $863M (+9% total, +3% organic); reported EPS $1.62 (+13%), adjusted EPS $2.04 (+11%).
IDEX Q3 adj EPS $1.90; sales flat organic; full-year GAAP EPS guidance lowered to $6.65-$6.70
GAAP diluted EPS $1.57 vs $2.75 prior year; adjusted diluted EPS $1.90 vs $2.12, down 10%.
IDEX completes acquisition of Mott Corporation, expanding material science capabilities
Acquisition of Mott, leader in sintered porous materials and flow control, completed Sept 5, 2024.
IDEX Q2 sales and profit miss; cuts full-year guidance; announces $1B Mott acquisition
Q2 sales $807M, down 5% (4% organic); GAAP EPS $1.86 (up 2%), adjusted EPS $2.06 (down 6%).
IDEX to acquire Mott Corporation for $1B cash to strengthen applied materials science capabilities
Net transaction value ~$900M after $100M PV of expected tax benefits; 19x forecasted 2024 EBITDA (low-20s margin).
IDEX Q1 sales $801M, -6% organic; adj. EPS $1.88 beats; FY guidance held
Reported diluted EPS $1.60 (-13% YoY); adjusted EPS $1.88 (-10%), above expectations.
IDEX Q4 sales -3%, adjusted EPS $1.83 (-9% YoY); FY2024 adjusted EPS guidance $8.15-$8.45
Q4 sales $789M (-3%, -6% organic); GAAP EPS $1.43 (-16%), adjusted EPS $1.83 (-9%).
IDEX Q3 adjusted EPS $2.12, revenue $793M; raises FY EPS guidance to $8.13-$8.18
Q3 net sales $793.4M, down 4% (-6% organic); diluted GAAP EPS $2.75, up 17% YoY.
IDEX CFO William Grogan resigns; Allison Lausas appointed interim CFO
William K. Grogan resigns as SVP & CFO effective Sept 15, 2023, to pursue new opportunity; departure not due to any disagreement.
IDEX reports record Q2 sales $846M; lowers FY adjusted EPS guidance to $7.90-$8.00 on HST weakness
Record Q2 sales $846.2M (+6% overall, +3% organic); reported EPS $1.82, adj. EPS $2.18 (+8%).
Record Q1 sales $845M (+13% YoY); reported EPS $1.84, adjusted EPS $2.09 (+7% vs $1.96).
IDEX reports record 2022 EPS of $7.71; guides 2023 adj. EPS $8.50-$8.80
Q4 revenue $810.7M (+13%), adj. EPS $2.01 (+18%); FY rev $3.18B (+15%), adj. EPS $8.12 (+18%)
IDEX draws $368M in credit facilities to fund Muon B.V. acquisition
Drew $200M from term credit facility on Nov 10, 2022.
IDEX Q3 record EPS $2.36 (adjusted $2.14), sales $824M +16%, raises FY guidance
Record Q3 sales $824M (+16% overall, +15% organic YoY); operating margin 24.5% (adj. 24.9%).
IDEX acquires Muon Group for €700M to expand precision tech platform
All-cash deal valued at €700 million; expected close in Q4 2022 subject to regulatory approvals.
IDEX Q2 EPS $1.81 beats; adjusted EPS $2.02; raises FY22 guidance
GAAP EPS $1.81 (up 35% YoY); adjusted EPS $2.02 (up 15%); revenue $796M (+16% overall, +12% organic).
IDEX reports record Q1 EPS $1.83 (adj. $1.96); sales $751M +15% YoY
Record reported EPS $1.83, up 24% YoY; adjusted EPS $1.96, up 21% vs. Q1 2021.
Record Q4 EPS $1.55 on sales $714.8M (+16% overall, +11% organic vs Q4 2020); full year EPS $5.88 (+19%).
IDEX Q3 2021: record sales $712M, EPS $1.51; adjusted EPS $1.63; raises FY guidance
Record orders $774.2M (+36% overall, +28% organic); record sales $712.0M (+23%, +15% organic).
IDEX reports record Q2 sales and orders; raises full-year adjusted EPS guidance
Record orders $751.0M (+44% overall, +39% organic) and record sales $685.9M (+22% overall, +17% organic).
On May 20, 2025, the Company appointed Akhil Mahendra as interim Chief Financial Officer of the Company, effective May 30, 2025, to hold the position of interim Chief Financial Officer until his successor is appointed.
On May 19, 2025, Abhishek Khandelwal, Senior Vice President and Chief Financial Officer of IDEX Corporation (the “Company”), notified the Company of his decision to resign from his position, effective May 30, 2025, to pursue a new professional opportunity.
two current directors, David C. Parry and Livingston L. Satterthwaite, provided the Company notice that they will be retiring from the Board immediately following the Company’s 2025 Annual Meeting of Stockholders and will not be standing for re-election.
two current directors, David C. Parry and Livingston L. Satterthwaite, provided the Company notice that they will be retiring from the Board immediately following the Company’s 2025 Annual Meeting of Stockholders and will not be standing for re-election.
On October 25, 2023, IDEX Corporation (the “Company”) announced the appointment of Abhishek Khandelwal as Senior Vice President and Chief Financial Officer of the Company, effective November 20, 2023.
In connection with his appointment, on November 20, 2023, Allison S. Lausas, will cease serving as Interim Chief Financial Officer and will continue serving as the Company’s Vice President and Chief Accounting Officer.
the resignation of William K. Grogan as the Company’s Senior Vice President and Chief Financial Officer, each effective September 15, 2023.
the appointment of Allison S. Lausas as interim Chief Financial Officer of the Company
IDEX Corporation notified Marc Uleman, Senior Vice President, Group Executive, Health & Science Technologies, of the elimination of his position, effective September 11, 2023.
On September 19, 2022, William M. Cook notified IDEX Corporation (the “Company”) of his decision to retire from the Board of Directors of the Company (the “Board”) and as Non-Executive Chairman of the Board, effective October 1, 2022.
Katrina L. Helmkamp has been appointed by the Board as its new Non-Executive Chair, effective October 1, 2022.
On June 15, 2022, the Board of Directors (the "Board") of IDEX Corporation (the "Company") appointed Alejandro Quiroz Centeno to serve as a member of the Board
Max materiality 0.85 · Median 0.60 · Most common event earnings